(Q44053792)

29 November 2017

Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome (English)

1 reference

29 November 2017

1 reference

Zagars GK

1

1 reference

PubMed ID

7533459

29 November 2017

Pollack A

series ordinal

2

1 reference

PubMed ID

7533459

29 November 2017

language of work or name

English

0 references

publication date

1 March 1995

1 reference

29 November 2017

1 reference

29 November 2017

45

1 reference

29 November 2017

476-483

1 reference

29 November 2017

3

1 reference

The role of radiation therapy in stages A2 and B adenocarcinoma of the prostate

29 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Definitive therapy for prostate carcinoma: Mayo Clinic results at 15 years after treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Management of cancer of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Estimation of confidence limits for the cumulative probability of survival in life table analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

Relationship of tumor DNA-ploidy to serum prostate-specific antigen doubling time after radiotherapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

The hazard of accelerated tumor clonogen repopulation during radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

The effect of overall treatment time on the outcome of definitive radiotherapy for localized prostate carcinoma: the Radiation Therapy Oncology Group 75-06 and 77-06 experience

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2980019-3

7 January 2021

10.1016/S0090-4295(99)80019-3

Identifiers

DOI

1 reference

29 November 2017

1 reference

PubMed ID

7533459